Eydis Bio, Inc.
Publicly observedDurham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Durham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Eydis Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MWWCM7JMBCF1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant14 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy
USD 406,496.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jul 2024Publicly observed
NIH SBIR/STTR award: Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
USD 1,417,658.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.